Hoth Therapeutics Files 8-K

Ticker: HOTH · Form: 8-K · Filed: 2025-06-20T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, filing, financials

Related Tickers: HOTH

TL;DR

HOTH filed an 8-K on 6/20 for events on 6/18 - details pending.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting other events and financial statements as of June 18, 2025. The filing does not contain specific details about the nature of these events or financial figures.

Why It Matters

This 8-K filing indicates that Hoth Therapeutics has reported significant events and financial statements, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial statements without immediate disclosed material changes.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Hoth Therapeutics in this 8-K filing?

The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.

What is the significance of the 'Financial Statements and Exhibits' being filed?

The filing indicates that financial statements and exhibits are being submitted, but the specific content or financial figures are not detailed in the provided excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on June 18, 2025.

What is Hoth Therapeutics, Inc.'s state of incorporation and principal executive office location?

Hoth Therapeutics, Inc. is incorporated in Nevada and its principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 066, New York, NY 10036.

What is the SEC file number and CIK for Hoth Therapeutics, Inc.?

The SEC file number for Hoth Therapeutics, Inc. is 001-38803, and its Central Index Key (CIK) is 0001711786.

From the Filing

0001213900-25-055834.txt : 20250620 0001213900-25-055834.hdr.sgml : 20250620 20250620080013 ACCESSION NUMBER: 0001213900-25-055834 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250618 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250620 DATE AS OF CHANGE: 20250620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251059114 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0246204-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-06-18 2025-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) June 18, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐               Item 8.01 Other Events.   On June 18, 2025, Hoth Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market, LLC (“Nasdaq”) stating that because the Company’s common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).   On June 18,

View on Read The Filing